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TherapeuticsImmunotoxins are chimeric proteins comprising a speciﬁc cellular targeting domain linked to a
cytotoxic factor. Here we describe the design and use of a novel, peptide-based immunotoxin that
can initiate selective cytotoxicity on ErbB2-positive cells. ErbB2 is a receptor tyrosine kinase that
is overexpressed in the tumor cells of approximately 30% of breast cancer patients. Immunotoxin
candidates were designed to incorporate a targeting ligand with afﬁnity for ErbB2 along with a
membrane lysin-based toxin domain. One particular peptide candidate, NL1.1-PSA, demonstrated
selective cytotoxicity towards ErbB2-overexpressing cell lines. We utilized a bioengineering strategy
to show that recombinant NL1.1-PSA immunotoxin expression by Escherichia coli also conferred
selective cytotoxicity towards ErbB2-overexpressing cells. Our ﬁndings hold signiﬁcant promise
for the use of effective immunotoxins in cancer therapeutics.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the biggest challenges facing cancer treatment is the
development of resistance to chemotherapy [1]. In order to combat
this treatment barrier, various attempts at specialized, targeted
therapies are emerging. Among them are the concepts of gene
therapy [2] and recruitment of the host immune system to ﬁght
against tumor formation and progression [3–5], although each
approach is hampered with its own set of limitations.
Importantly, many advancements are being made with small
molecule inhibitors toward receptor tyrosine kinases that are often
overexpressed in cancers, but the majority of current FDA-ap-
proved inhibitors are not targeted to a particular molecule, fre-
quently resulting in strong side effects and premature drug
resistance [6]. Therefore, the development of more speciﬁc tar-
geted therapies is of critical importance. One such therapeutic
approach that has begun to garner interest is the development of
immunotoxins [7,8].Immunotoxins are chimeric proteins containing a targeting
moiety conjugated to a toxin component [8]. The targeting moiety
is frequently an antibody or recombinant antibody fragment [9], a
design that has recently shown promise in treating blood cancers
such as leukemia [10].
The toxin component of immunotoxins can be synthesized from
a variety of sources, including derivatives from plants or bacteria
[7,8]. For years, attempts have been made to engineer live bacterial
cells to target tumors and induce cell death [11,12]. However, due
to immune rejection and additional adverse side effects, focus has
shifted to using bacterial-derived agents for cancer treatment
instead [11]. At present, the only immunotoxin approved by the
FDA is denileukin diftitox, a protein immunotoxin consisting of
interleukin 2 (IL-2) as the targeting ligand, and a truncated version
of the Diphtheria bacterial toxin [13,14]. It is used for the treat-
ment of recurrent cutaneous T-cell lymphomas [15]. Similar to
the ADP-ribosylating action of Diphtheria toxin (which acts to
arrest protein translation), another immunotoxin strategy has been
developed using the protein secreted by Pseudomonas aeruginosa,
Pseudomonas exotoxin A [16]. Recent conjugation of this toxin to
melanocyte-stimulating hormone has proven highly effective in
the treatment of melanoma in mice [17]. However, one notable
disadvantage to the use of these bacterial exotoxins is the require-
ment that the toxin be internalized by the targeted cell to exert its
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can directly impact the efﬁcacy of the immunotoxin [16].
Here, we report the design and evaluation of a novel peptide-
based immunotoxin with speciﬁcity toward ErbB2. ErbB2 is a
receptor tyrosine-protein kinase that is ampliﬁed in approximately
30% of breast cancers [18] and is of strong interest in the develop-
ment of targeted therapies [19]. Unlike the aforementioned
immunotoxins, the toxin moiety of our peptide immunotoxin is
based on a small, peptide cytolysin that can act at the plasma
membrane to disrupt membrane integrity and induce cell death.
Such a mechanism thereby elicits higher chances of evading the
chemotherapy resistance commonly found in ErbB2-positive can-
cers [20,21]. Additionally, we describe a rapid, PCR-based gene
synthesis strategy to engineer the NL1.1-PSA gene for Escherichia
coli-based recombinant protein expression, suggesting that diverse
E. coli-based genetic libraries of active immunotoxin candidates
can be easily produced for activity screenings. Our ﬁndings high-
light the feasibility of using small, peptide-based immunotoxins
for potential targeted cancer therapies.
2. Materials and methods
2.1. Peptides used for study
All peptide candidates used for this study were synthesized by
Genscript peptide services (Genscript USA, New Jersey). All pep-
tides were obtained with >70% purity, as veriﬁed by Genscript.
All peptides were diluted in DMSO in appropriate concentrations
for testing prior to use and veriﬁed for solubility as necessary.
Resuspended peptides were stored in 80 C until use.
2.2. Cell culture
MCF-10A cell lineswere cultured as described previously [22]. In
brief, cells were grown in DMEM/F12 (Invitrogen) with 5% horse
serum (Invitrogen) and supplementedwith insulin, hydrocortisone,
cholera toxin, epidermal growth factor (EGF), and 1% penicillin/
streptomycin (Invitrogen). HACAT cells were grown in DMEM
(Invitrogen) supplemented with 10% bovine serum albumin.
2.3. Retroviral transduction
The pBabe-Puro-based retroviral vector encoding wild-type
ErbB2 was used to generate stable cell lines. Retroviruses were
produced by cotransfection of HEK293T cells with pCLAmpho
and target DNA using lipofectamine (Invitrogen). Virus was har-
vested and ﬁltered at 24 and 48 h post-transfection and retroviral
infections were carried out in the presence of 8 lg/mL of polybrene
(Sigma–Aldrich). Following transduction, cells were selected with
2 lg/mL puromycin for two weeks. Overexpression efﬁciency was
measured by immunoblotting.
2.4. Immunoblotting
Cells were lysed in a buffer containing 1% NP-40, 1 lg/mL apro-
tinin, 5 lg/mL leupeptin, and 20 lg/mL phenylmethylsulfonyl
(PMSF) and cleared by centrifugation. Lysates were normalized
by BCA assay (Pierce Biotechnology). The following antibodies
were used for immunoblotting: b-Actin (Sigma–Aldrich), c-erbB-2
(Dako).
2.5. Cell death assay
MCF-10A cells were plated in 48-well plates and grown to
approximately 50% conﬂuence. Cells were then treated with
immunotoxins at the indicated doses for 24 h and then assayedfor cell death by staining with Ethidium Homodimer-1 (EthH-1,
Life Technologies). Cell media was collected into eppendorf tubes
and set aside. Attached cells were washed with PBS, which was
then transferred to the appropriate eppendorf tube. Attached cells
were then incubated in a solution of 4 lM EthH-1 in PBS in the
dark at room temperature for 40 min. After 40 min, ﬂuorescence
was read with a bottom read on a SpectraMaxM5 plate reader with
the following settings: excitation at 528 nm, emission at 617 nm,
and a cutoff ﬁlter of 590 nm. After reading, saponin was added to
each well to a ﬁnal concentration of 0.1%/well to make all cells
penetrable for EthH-1. The plate was then incubated in the dark,
shaking gently, at room temperature for 30 min before doing a
ﬁnal ﬂuorescence read as described above. Meanwhile, the col-
lected media and PBS wash were spun down and pelleted debris
and/or cells were washed once with PBS and centrifuged. The pel-
let was then resuspended in a solution of 4 lM EthH-1, 0.1% sapo-
nin, and PBS and transferred to a clear-bottom 96-well plate for
each condition. The plate was incubated in the dark at room tem-
perature for 15 min before being read with the ﬂuorescence set-
tings as described above. A percentage of total dead cells
(including both attached and detached dead cells) was generated
for each condition and normalized by cell type to DMSO control.
P values were determined using a 2-tailed t test.
2.6. In vitro genetic construction of NL1.1-PSA immunotoxin gene via
primer-based PCR
The synthesized NL1.1-PSA peptide with amino acid sequence
MYWGDSHWLQYWYEGFFALIPKIISSPLFKTLLSAVGSALSSSGGQE was
reverse translated using online software [23] and E. coli optimized
codon tables. The gene sequence of NL1.1-PSA was determined to
be 50-ATGTATTGGGGCGATAGCCATTGGCTGCAGTATTGGTATGAAG
GCTTTTTTGCGCTGATTCCGAAAATTATTAGCAGCCCGCTGTTTAAA-
ACCCTGCTGAGCGCGGTGGGCAGCGCGCTGAGCAGCAGCGGCGGC-
CAGGAA-30. Ten overlapping oligonucleotide primers, 20mers (±4),
were designed using Gene2Oligo software [24,25] with an average
Tm of 71.75 C. Sequences of primers used to build the NL1.1-PSA
gene were:
R0:TCGCCCCAATACATAGGCC
F0:GGCCTATGTATTGGGGCGATAGCCATTGGCTGCAGT
R19:GCAAAAAAGCCTTCATACCAATACTGCAGCCAATGGCTA
F36:ATTGGTATGAAGGCTTTTTTGCGCTGATTCCGAAAATTATTA
GCAG
R58:CAGGGTTTTAAACAGCGGGCTGCTAATAATTTTCGGAATCA
GC
F82:CCCGCTGTTTAAAACCCTGCTGAGCGCGGTGGGCA
R101:CTGCTGCTCAGCGCGCTGCCCACCGCGCTCAG
F117:GCGCGCTGAGCAGCAGCGGCGGCCAGGAAATG
R133:GCTGTCCATACATACATCAGGCATTTCCTGGCCGCCG
R149:CCTGATGTATGTATGGACAGC
PCR using these primers was conducted initially to synthesize
overlapping products including a small portion of the full-length
PCR product (Settings: 95 C for 2 min, then 30 cycles of 95 C for
30 s, 55 C for 30 s, 72 C for 1 min. The average Tm of the primers
was 71.75 C). A portion of this reaction was used as a template for
a second round of PCR using a set of primers (N-PSA-FWD2:50-
TACAGGGGATCCGAACTCATGTATTGGGGCGATAGCCATTGG-30; N-
PSA-REV2:50-GACTTACTCGAGACTAGCTTATTATTCCTGGCCGCCGCT
GCT-30) designed in order to amplify the ﬁnished gene product of
the desired length (183 bp). Additionally, restriction enzyme sites
were incorporated into these sets of primers (FWD/BamH1 and
REV/Xho1) for downstream cloning purposes, with two stop
codons at the end of the sequence. Second PCR was conducted with
the following settings: 30 cycles of 95 C for 30 s, 57 C for 30 s, and
AB
Fig. 1. Design of ErbB2-targeting immunotoxins. Schematic of the immunotoxin
design. Any combination of one ligand moiety and one toxin moiety from the lists
can be inserted into the diagram to demonstrate how the pairs can be conjugated
together. Of note, the location on the amino- and carboxy-terminal ends may be
exchanged to create two different immunotoxins from the same two moieties (A).
Table listing the amino acid sequences of the moieties denoted in panel A (B). Please
see the references associated with each of the following characters: a [28], [[29], +
[26], ¥ [31].
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electrophoresis and resulted in a robust band consistent with the
synthesized gene (183 bp).
2.7. Cloning of NL1.1-PSA immunotoxin gene into the TOPO and
pET28b vectors
The synthesized NL1.1-PSA PCR gene was cloned using primer-
integrated restriction sites (BamH1, Xho1) into a modiﬁed pET-28b
plasmid containing an N-terminal maltose binding protein (MBP)
fusion domain as described previously [26]. Successful plasmids
containing an N-terminal MBP fusion protein to the NL1.1-PSA
gene were veriﬁed by sequencing. These plasmids were subse-
quently transformed into BL21 E. coli cells and used for protein
induction and cell-cytotoxicity studies.
2.8. E. coli-based production of NL1.1-PSA and cell cytotoxicity
evaluation
To determine cytotoxicity of E. coli-based production of NL1.1-
PSA on host cells, HACAT and MCF-10A-derived cell lines were
plated to 50–70% conﬂuency on 12-well tissue culture plates. Cells
were washed three times to remove penicillin/streptomycin-
supplemented media and incubated with standard antibiotic-free
media. BL21 E. coli containing the pET28b-MBP-NL1.1-PSA fusion
gene plasmid was added from an LB diluted colony (O.D 600 0.05)
at a 1:100 dilution directly into the antibiotic-free media. IPTG
was added at various concentrations (0.4 mM, 0.8 mM, 1.2 mM,
1.6 mM) directly to the wells immediately following addition of
bacteria, and theplateswere incubated for 4 h at in a 37 C incubator
with 5%CO2. Following the incubationperiod, allwellswerewashed
three times in cold PBS and cells were immediately counted and
imaged using phase microscopy (Zeiss axiovert).
3. Results
3.1. Developing chemically synthesized ErbB2-targeted immunotoxins
Although ErbB2 has no known ligand [27], previous studies
have identiﬁed small peptide fragments with a strong afﬁnity forthe ErbB2 receptor [28,29]. In our immunotoxin design strategy
we therefore conjugated these ErbB2 receptor targeting ligands
to several peptide sequence candidates that were previously
demonstrated to have intrinsic ability to lyse cellular membranes.
In particular, the three peptide toxins tested were composed of: 1.
SP – a proline-substituted derivative of the Streptolysin S hemoly-
sin from Group A Streptococcus that was shown to have intrinsic
cytolytic activity as a peptide [30]; 2. PSA, an 18-residue peptide
adapted from the N-terminus of the Pardaxin hemolysin [31]; 3.
S32, a synthetically designed toxin from our bacteriocin screening
library that was found to exert hemolytic activity ([26]; Lee, SW,
unpublished data). Based on this template, we designed a series
of immunotoxin-based synthetic peptides with two components:
an ErbB2 targeting moiety and a toxin moiety. The toxin and tar-
geting moieties were paired in various combinations, some with
the targeting moiety at the amino-terminus and toxin moiety on
the carboxy-terminus (Fig. 1A), others with the two moieties
inverted on terminal ends. These immunotoxin peptide candidates
were then synthesized as lyophilized peptides from Genscript at a
>70% purity, and dissolved in DMSO prior to testing.
3.2. Identiﬁcation of a toxic and speciﬁc chemically synthesized ErbB2-
targeted immunotoxin
Although the targeting moieties used in the development of
the immunotoxins had previously been shown to have speciﬁcity
toward the ErbB2 receptor [28,29], it was not determined
whether these targeting moieties would still retain speciﬁc bind-
ing interactions with their cognate receptors if they were conju-
gated to an additional peptide sequence. Furthermore, the
cytolytic peptide domains that we incorporated into our
immunotoxin strategy needed to remain active even after the
incorporation of a targeting ligand. Therefore it was critical that
all of the immunotoxin candidates that we produced would be
evaluated both for their inherent cytotoxicity as well as targeting
speciﬁcity. In order to do so, a pair of isogenic tissue culture cell
lines was established. MCF-10A cells are a non-transformed
mammary epithelial cell line that normally expresses very low
levels of ErbB2 (Fig. 2A, MCF-10A-EV). Using retroviral transduc-
tion we engineered cells to overexpress ErbB2 (MCF-10A-ErbB2)
as compared to the control (MCF-10A-EV; Fig. 2A). Using this
set of isogenic cell lines, we assessed the toxicity and speciﬁcity
of six synthetic immunotoxins by treating the cells with the
immunotoxin and assaying for total cell death following a 24-h
incubation. Three immunotoxins exhibited dose-dependent cell
toxicity that was not speciﬁc to ErbB2-positive cells (Fig. 2B)
and two immunotoxins exhibited very low, nonspeciﬁc toxicity
(Fig. 2C). However, one immunotoxin, NL1.1-PSA, exhibited both
toxicity and high speciﬁcity toward ErbB2-positive cells in a
dose-dependent fashion (Fig. 2D). Of all immunotoxins screened,
NL1.1-PSA was the only immunotoxin to achieve targeted action
toward cells overexpressing the ErbB2 receptor.
3.3. Genetically engineered NL1.1-PSA immunotoxin gene and
E. coli-based peptide expression
Numerous factors including inconsistent or loss of purity
between batches, poor solubility, the need for harsh solvents, low
production rate, and high cost of production, among others, can
challenge synthetic production of small peptides. Given these con-
siderations, we designed a primer-based, two step PCR method to
synthetically produce the gene encoding the NL1.1-PSA candidate
for cloning into an E. coli-based protein expression vector. A
codon-optimized sequence corresponding to the NL1.1-PSA gene
and overlapping primers to construct the gene sequence were
designed using the Gene2Oligo software. A ﬁrst round of PCR using
Fig. 2. The synthetic NL1.1-PSA immunotoxin is both toxic and speciﬁc to ErbB2-positive cells. Parental MCF-10A cells were engineered to overexpress ErbB2 (MCF-10A-
ErbB2). MCF-10A cells transduced with virus containing an empty vector were used as a control (MCF-10A-EV). Conﬁrmation of overexpression was done by immunoblotting.
b-Actin was used as a loading control (A). MCF-10A-EV and MCF-10A-ErbB2 cells were grown to 50% conﬂuence and treated with the indicated immunotoxin. Cells
incubated with the immunotoxin at the indicated doses for 24 h were subsequently assayed for cell death by ﬂuorescence reading following Ethidium Homodimer-1 staining.
The percentage of dead cells was normalized to the DMSO control in each cell type. Error bars represent standard deviation (B–D).
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full-length gene sequences, which were then subjected to a second
round of PCR using two additional primers designed to amplify
only the full-length product (Fig. 3A). Successful clones were veri-
ﬁed by sequencing and subsequently cloned into a pET28b-MBP
fusion vector for protein expression using an IPTG-inducible BL21
E. coli strain (Invitrogen). Induction tests determined that a band
corresponding to the correct size of MBP-NL1.1-PSA could be
observed in bacterial cell lysates as well as in culture supernatants
(Alber, D., Thomas, C.T., unpublished). Since production of small
peptides has been known to be toxic to E. coli, we deduced that
mature toxin might be produced and signiﬁcantly accumulated
in the supernatant of the culture following peptide induction. In
order to test whether E. coli induction of MBP-NL1.1-PSA produces
a secreted product that is cytotoxic, we ﬁrst evaluated general cel-
lular toxicity using HaCaT cells, a human keratinocyte cell line that
expresses moderate levels of ErbB2 [32,33]. BL21 E. coli trans-
formed with the MBP-NL1.1-PSA expression plasmid were added
directly to HaCaT cells. As observed in Fig. 3B, NL1.1-PSA expres-
sion in BL21 E. coli using increasing amounts of IPTG induction
(0.4 mM, 0.8 mM, 1.6 mM) resulted in increased cellular cytotoxi-
city, as observed by total HaCaT cells adhered to the plate. BL21E. coli producing the MBP only control (Fig. 3B, upper panel) did
not show signiﬁcant cellular cytotoxicity, indicating that cell death
is speciﬁc to the MBP-NL1.1-PSA toxin. To further assess the efﬁ-
cacy of the E. coli-based NL1.1-PSA product compared to the effects
that we observed with the synthesized peptide (Fig. 2D), we
repeated the experiment using the isogenic MCF-10A cell lines.
MCF-10A-EV and MCF-10A-ErbB2 cells were plated and exposed
to BL21 E. coli expressing the MBP-NL1.1-PSA toxin with IPTG
induction (1.6 mM). Incubation of the immunotoxin-producing
E. coli strain on these cells resulted in similarly cytotoxic phenotypes,
with decreases in MCF-10A-ErbB2 cell number (Fig. 3C). However,
there was a marked difference in the cytotoxic effects between the
ErbB2-positive and negative cell lines, with signiﬁcantly increased
cytotoxicity observed in the ErbB2-positive cells (Fig. 3C). Although
it is difﬁcult to quantify the actual amount of immunotoxin pro-
duced by our E. coli strains during our experiment, our initial
induction tests of NL1.1-PSA production showed estimated con-
centrations of 0.1–0.5 mg/mL total protein from a 5 mL E. coli cul-
ture. Taken together, these data establish both toxicity and
speciﬁcity of the naturally produced NL1.1-PSA. Furthermore,
these data demonstrate that immunotoxin candidates can be
evaluated using an E. coli-based protein expression system.
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Fig. 3. E. coli production of NL1.1-PSA is both toxic and speciﬁc to ErbB2-positive cells. Schematic of how overlapping primers were used to build the plasmids containing the
MBP-bound NL1.1-PSA sequence via PCR (A). HaCaT cells were grown to 50% conﬂuence and subsequently co-cultured with E. coli BL21 cells containing the MBP-NL1.1-PSA
plasmid or an MBP-only control plasmid for 4 h. Increasing amounts of IPTG (from left to right: no IPTG, 0.4 mM, 0.8 mM, 1.6 mM) induced continuous immunotoxin protein
productionbyE. coliBL21cells. Representative images are given following IPTG inductionwith concentrations as follows: 0 mM(no IPTG), 0.4 mM,0.8 mM, and1.6 mM.Total cell
number of HaCaT cells present following BL21 induction is given in graph. Error bars represent SEM (B). MCF-10A-EV andMCF-10A-ErbB2 cells were grown to50% conﬂuence
and subsequently co-cultured with BL21 cells containing the MBP-NL1.1-PSA plasmid or an MBP-only control plasmid for 4 h. Representative images are given following IPTG
induction at a ﬁnal concentration of 1.6 mM. Total cell number ofMCF-10A-EV andMCF-10A-ErbB2 cells present following BL21 induction is given. Error bars represent SEM (C).
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Resistance to chemotherapy is a prominent barrier in treating
cancer patients [1] and cancers characterized by the overexpres-
sion of ErbB2 are no exception [20,21]. As a noted receptor found
enriched in cancer cells [18], ErbB2 has been an attractive target
for chemotherapies. Various groups have identiﬁed unique
sequences that have a strong afﬁnity for the receptor [28,29] and
utilizing modiﬁed variants of these sequences conjugated to a
cytolytic peptide, we have successfully achieved speciﬁc cell killing
of ErbB2-positive cells (Figs. 2D and 3C). Given that the NL1.1-PSA
toxin candidate likely exerts its effects at the plasma membrane,
we speculate that mechanisms of chemoresistance that involve
alterations in intracellular signal transduction, up-regulation of
multi-drug resistance genes, or defective vesicular trafﬁcking
would not signiﬁcantly alter the efﬁcacy of this toxin. This is in
contrast to previously developed immunotoxins that require inter-
nalization for activity [8,16]. Furthermore, penetrance into solid
tumors is a prominent obstacle in treatments with immunotoxins
[8], likely due in part to the requirement for internalization. We
have designed our cytolysin-derived immunotoxin strategy such
that the capacity of NL1.1-PSA to act at the cell membrane of
ErbB2-positive cell populations may serve to increase overall clear-
ance of cancer cells from solid tumor surfaces.
Notably, a previous attempt at utilizing an ErbB2-targeting
immunotoxin resulted in hepatotoxicity during clinical trials
[34]. During this study, through the use of a monoclonal ErbB2
antibody, it was concluded that expression of ErbB2 in normal
hepatocytes was responsible for the toxicity observed. Recent
studies, however, have utilized the FDA-approved ErbB2 detection
kit, HercepTest [35], to examine ErbB2 expression in patient
samples and concluded that ErbB2 is minimally expressed in
non-neoplastic tissues [36]. Therefore, the hepatotoxicity previously
observed may be due to general off-target effects rather than
the high expression of ErbB2 in hepatocytes. These data, in combina-
tion with the speciﬁcity exhibited by our immunotoxin (Figs. 2D
and 3C), provide conﬁdence that our toxin would display distinct
sensitivities between ErbB2-overexpressing breast cancer cells
and normal cells expressing minimal endogenous ErbB2, thereby
preventing off-target toxicity.
Finally, the genetic engineering strategy presented here for the
production of our peptide-based immunotoxins (Fig. 3A) allows for
the opportunity to rapidly diversify toxin and ligand sequences
that may have improved activity over the originally tested NL1.1-
PSA toxin. Changes to the ligand binding motif using this strategy
would also enable the immunotoxin to target to numerous vari-
eties of solid tumor tissues, given a signature of overexpression
markers, while still harboring the capacity to lyse the cells upon
contact with the PSA toxin moiety. Hence the immunotoxin pre-
sented here is not necessarily limited to ErbB2-positive cells but
could be engineered to treat a vast expanse of cancers and/or other
diseases.
Importantly, we demonstrate that the peptide-based immuno-
toxin genetic engineering method that we describe herein could
be coupled with E. coli induction and direct cytotoxicity evaluation
using a simple tissue- culture based screen. We propose that such a
method could be improved to establish a high-throughput screen
for rapidly identifying new immunotoxin candidates that would
have advantages in cost and time over screens using individually
synthesized peptides.
Overall, we acknowledge that further studies are required to
explore the clinical application of the NL1.1-PSA immunotoxin pre-
sented here, including the use of 3-dimensional in vitro assays to
more closely simulate tumor environments in situ as well as efﬁ-
cacy using in vivo animal models. However, our strategy to design
a small, peptide-based immunotoxin that exerts its toxic effects atthe cell surface of cancer cells holds immense promise in overcom-
ing the resistance to chemotherapy as either a ﬁrst or second line
treatment option. These data open the door to future research
aimed at eliminating solid tumors in a way that minimizes resis-
tance to treatment and enhances overall patient survival.5. Conclusions
ErbB2 is a receptor tyrosine-kinase that is overexpressed in
the tumor cells of approximately 30% of breast cancer patients,
and cancer cells with ErbB2 overexpression frequently acquire
resistance to traditional chemotherapies. This substantiates the
need for the development of additional, speciﬁc therapeutics
targeting ErbB2-positive cells. Here we describe the development
and testing of a peptide-based immunotoxin, NL1.1-PSA, that
exhibits ErbB2-speciﬁc cytotoxicity. The utilization of the immuno-
toxin described here could overcome the likelihood of chemore-
sistance and thereby more effectively eliminate ErbB2-positive
breast cancer cells. We also present an E. coli-based bioengineer-
ing approach for the production and testing of peptide immuno-
toxin candidates. This would enable future research to expand on
our ﬁndings with ErbB2-positive cells to engineer immunotoxins
with targeting speciﬁcity toward other receptors and markers of
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